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Abstract
Necrotizing enterocolitis (NEC) affects predominantly preterm infants, who have specific risk factors leading to
intestinal dysbiosis. Manipulations of gut microbiota through probiotics have the potential to prevent NEC.
The aim of this systematic review and meta-analysis was to evaluate the effect of probiotics for NEC prevention in
preterm infants, with a focus on specific strains, microbiological strength of currently available studies, and high-risk
populations.
PubMed and the Cochrane Library were searched for trials published within 4th February 2015. Randomized-controlled
trials reporting on NEC and involving preterm infants who were given probiotics in the first month of life were
included in the systematic review.
Twenty-six studies were suitable for inclusion in the meta-analysis.
Data about study design, population, intervention and outcome were extracted and summarized independently by
two observers. Study quality and quality of evidence were also evaluated.
Fixed-effects models were used and random-effects models where significant heterogeneity was present. Subgroup
analyses were performed to explore sources of heterogeneity among studies. Results were expresses as risk ratio (RR)
with 95 % confidence interval (CI).
The main outcome was incidence of NEC stage ≥2 according to Bell’s criteria.
Probiotics prevented NEC in preterm infants (RR 0.47 [95 % CI 0.36–0.60], p < 0.00001). Strain-specific sub-meta-analyses
showed a significant effect for Bifidobacteria (RR 0.24 [95 % CI 0.10–0.54], p = 0.0006) and for probiotic mixtures (RR 0.39
[95 % CI 0.27–0.56], p < 0.00001). Probiotics prevented NEC in very-low-birth-weight infants (RR 0.48 [95 % CI 0.37–0.62],
p < 0.00001); there were insufficient data for extremely-low-birth-weight infants. The majority of studies presented
severe or moderate microbiological flaws.
Probiotics had an overall preventive effect on NEC in preterm infants. However, there are still insufficient data on the
specific probiotic strain to be used and on the effect of probiotics in high-risk populations such as extremely-low-birth-
weight infants, before a widespread use of these products can be recommended.
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Background
Necrotizing enterocolitis (NEC), which is one of the
most devastating neonatal diseases, has become a prior-
ity for research [1]. Despite great advances in neonatal
care, the morbidity, mortality and health-care costs dir-
ectly related to the disease are substantial: during hos-
pital stay, the economic burden of NEC in the United
States has been estimated as high as several billions USD
per year, which is approximately 20 % of the costs for
Neonatal Intensive Care Units in the country; further-
more, this estimate is likely to be much higher when the
costs of long-term care of survivors are taken into ac-
count [2].
NEC is a multifactorial disease: prematurity is a well-
recognized risk factor, and approximately 90 % of the in-
fants who develop NEC are born preterm [3]. This is
probably due to specific comorbidities of prematurity,
such as immunodeficiency, use of broad-spectrum anti-
microbials, delayed enteral feeding and low availability
of human milk.
Recently, research has focused on the role of gut
microbiota and its manipulations, such as the use of
probiotics, on disease and health status. Probiotics are
live–microorganisms which, when ingested in adequate
amounts, confer a health-benefit to the host through an
interaction with gut microbiota [4]. The intestinal micro-
biota undergoes dynamic changes during childhood. Gut
colonization in preterm infants occurs differently than in
healthy term newborns [5], and preterm infants frequently
have delayed and aberrant acquisition of the “normal” di-
gestive flora. Recent studies performed in preterm foe-
tuses and infants demonstrated that amniotic fluid and
meconium are not sterile, suggesting an intrauterine ori-
gin of gut microbiota [6, 7]; after birth, the preterm
infant’s immature intestine is exposed to an unique envir-
onment and to several iatrogenic manipulations, including
the use of broad-spectrum antibiotics. The subsequent in-
testinal dysbiosis is recognized as a risk factor for NEC: ac-
tually, it has been shown that preterm infants with NEC
have reduced bacterial gut diversity and different bacterial
strains compared to healthy controls [8]. In this perspec-
tive, provision of probiotics to preterm infants has the po-
tential to “normalize” the abnormal colonization pattern,
thus preventing the occurrence of the disease [9].
The use of probiotics for the prevention of NEC in pre-
term infants has been extensively investigated in many
randomized-controlled trials, whose results have been
summarized in several systematic-reviews and meta-
analyses [10, 11]. The authors of these meta-analyses,
which show that probiotics reduce NEC and mortality in
preterm infants, strongly encourage a change in practice,
promoting a widespread use of probiotics in this popula-
tion [11], and also claim that withholding probiotics from
high-risk neonates would be almost unethical [10].
However, the position of the American Academy of Paedi-
atrics is more cautious, highlighting the need for more
studies to address unanswered questions on the amount
and specificity of which probiotic or mixture of probiotics
should be used [12]. In addition, a recent systematic
review, which analyzed the level of evidence of
randomized-controlled trials on probiotics in preterm
infants, concluded that there is still insufficient evi-
dence to recommend routine probiotics use, but also
that present data are encouraging and justify further
research on specific probiotic products [13].
Actually, the beneficial effects of probiotics appear to be
strain-specific, and pooling data from studies using differ-
ent strains can result in misleading conclusions [14]. Fur-
thermore, currently available studies often lack specificity
in reporting correct identification of probiotic strain [15],
dosage regimen and duration, and gut colonization, which
are all fundamental to assess the ability of a probiotic to
confer a health benefit to the host [16].
The aim of this meta-analysis is thus to evaluate in de-
tail the effect of probiotics for the prevention of NEC in
preterm infants, with a focus on specific strains, on
microbiological strength of currently available studies,
and on high-risk populations.
Methods
Literature search
The study protocol was designed jointly by the members
of the Task Force on Probiotics of the Italian Society of
Neonatology.
A systematic review of published studies reporting the
use of probiotics for the prevention of NEC in preterm in-
fants was performed, following PRISMA guidelines [17].
Criteria for inclusion in the meta-analysis were the fol-
lowing: randomized and quasi-randomized controlled tri-
als involving preterm infants (gestational age <37 weeks)
and reporting on NEC (any stage, according to modified
Bell staging criteria [18, 19]); enteral administration of any
probiotic starting within one month of age, compared to
placebo or no treatment. Being the search strategy focused
specifically on NEC, data on different outcomes, such as
sepsis or mortality, which were reported in the studies re-
trieved by the literature search, were not evaluated by
meta-analysis.
A search was conducted in PubMed (http://www.
ncbi.nlm.nih.gov/pubmed/) for studies published before
4th February 2015, using the search string reported in
Fig. 1. This string was built up combining all the terms re-
lated to NEC and probiotics, using PubMed MeSH terms
and free-text words and their combinations through the
most proper Boolean operators, in order to be as compre-
hensive as possible. Similar criteria were used for searching
the Cochrane Library. The review was limited to studies
written in English and involving human subjects.
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The search was conducted by AA and LC: relevant
studies were identified from the abstract, and reference
lists of papers retrieved were searched for additional
studies. “Snowballing” technique was also used [20].
Data extraction and meta-analysis
Study details, including study population, character-
istics of the intervention, use of placebo, and out-
come, were assessed independently by AA and LC,
and checked by DG. Study quality was evaluated in-
dependently using the risk of bias tool as proposed
by the Cochrane collaboration (Chapter 8 of the
Cochrane Handbook of Systematic Reviews) [21]. In
addition, an assessment of the body of evidence
using the GRADE working group approach was used
in order to grade the quality of evidence. The evaluation
was carried out following the Chapter 12 of the Cochrane
Handbook [21] and classifying the evidence as high,
Fig. 1 Flow chart showing the search strategy and search results. The relevant number of papers at each point is given
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Table 1 Studies included in the systematic review and meta-analysis
Author, year Study
details
Study population Intervention Type of milk Placebo
- Strain
- Dose (D)
- Start of treatment (S)
- End of treatment (E)
Al-Hosni, 2012 [33] P Preterm infants with BW 501–1000 g, appropriate for
gestational age, and≤ 14 days of age at time of
feeding initiation
Lactobacillus rhamnosus GG LGG Non specified Extra milk
DB Bifidobacterium infantis
R D: 0.5 × 109 CFU each probiotic, OD
C S: first enteral feeding
Multic. E: discharge or until 34 w postmenstrual age
Bin-Nun, 2005 [40] P Preterm infants with BW < 1500 g, who began enteral
feeding on a weekday
Bifidobacterium infantis OMM, PFM HM or FM
B Streptococcus thermophilus
R Bifidobacterium bifidus
C D: 0.35 × 109 CFU each probiotic, OD
S: start of enteral feeding
E: 36 w postconceptual age
Braga, 2011 [35] P Inborn infants with BW 750–1499 g Lactobacillus casei HM Extra HM
DB Bifidobacterium breve
R D: 3.5 × 107 CFU to 3.5 × 109 CFU OD
C S: day 2
E: day 30, NEC diagnosis, discharge, death, whichever
occurred first
Costalos, 2003 [49] P GA 28–32 w Saccharomyces boulardii PFM MDX
R No major GI problem D: 1 × 109 CFU BD
C Not receiving antibiotics S: non-specified
Not receiving breast milk Median duration of probiotic supplementation: 30 days
Dani, 2002 [42] P Infants with GA < 33 w or BW < 1500 g Lactobacillus rhamnosus GG OMM, DM or FM MDX
DB D: 6 × 109 CFU OD
R S: first feed
C E: discharge
Multic.
Demirel, 2013 [28] P Preterm infants with GA ≤ 32 w and BW≤ 1500 g, who
survived to feed enterally
Saccharomyces boulardii HM, FM None
B D: 5 × 109 CFU OD
R S: first feed
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Table 1 Studies included in the systematic review and meta-analysis (Continued)
C E: discharge
Dilli, 2015 [44] P Preterm infants with GA <32 weeks and BW <1500 g,
born at or transferred to the NICU within the first week
of life and fed enterally before inclusion
Bifidobacterium HM, FM MDX powder
DB Lactis
R D: 5 × 109 CFU
C S: beyond d7 after birth
Multic. E: death or discharge (max 8 weeks)
Fernández-Carrocera,
2013 [32]
P Preterm infants with BW < 1500 g Lactobacillus acidophilus 1 CFU/g OMM, PFM None
DB Infants with NEC IA and IB were excluded Lactobacillus rhamnosus 4.4 × 108 CFU/g
R Lactobacillus casei 1 × 109 CFU/g
C Lactobacillus plantarum 1.76 × 108 CFU/g
Bifidobacterium infantis 2.76 × 107 CFU/g
Streptococcus thermophilus 6.6 × 105 CFU/g
Total D: 1 g powder OD
S: start of enteral feeding
E: non-specified
Jacobs, 2013 [26] P Preterm infants with GA <32 w and BW < 1500 g Bifidobacterium infantis BB-02 300 CFU × 106 HM, FM MDX powder
DB Streptococcus thermophilus Th-4 350 CFU × 106
R Bifidobacterium lactis BB-12 350 CFU × 106
C Total D: 1 × 109 CFU × 1.5 g maltodextrin powder OD
Multic. S: enteral feed ≥ 1 ml every 4 h
E: discharge or term corrected age
Kitajima, 1997 [52] P Preterm infants with BW < 1500 g Bifidobacterium breve YIT4010 OMM, FM after full enteral feeding
had been reached
Distilled water
R D: 0.5 × 109 CFU OD
C S: within 24 h of life
Duration of probiotic supplementation: 28 days
Lin, 2005 P Infants with BW< 1500 g, who started to feed enterally
and survived beyond day 7
Lactobacillus acidophilus OMM, DM None
M Bifidobacterium infantis
R D: ≥ 106 CFU each probiotic (=125 mg/kg), BD
C S: start of enteral feeding
E: discharge
Lin, 2008 P Preterm infants with GA < 34 w and BW≤ 1500 g, who
survived to feed enterally
Lactobacillus acidophilus NCDO 1746 HM, FM None
B Bifidobacterium bifidum NCDO 1453
R D: 1 × 109 CFU each probiotic (=125 mg/kg) BD
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Table 1 Studies included in the systematic review and meta-analysis (Continued)
C S: day 2 of age
Multic. Duration: 6 weeks
Manzoni, 2006 [37] P Infants with BW < 1500 g, ≥ 3 days of life, who started
enteral feeding with HM
Lactobacillus rhamnosus LGG OMM, DM None
DB D: 6 × 109 CFU/day
R S: day 3 of life
C E: end of the 6th week or discharge
Mihatsch, 2010 [43] P Preterm infants with GA < 30 w and BW≤ 1500 g Bifidobacterium lactis BB12 HM, PFM Indistinguishable
powder
R D: 2 × 109 CFU/kg 6 times a day
C S: start of enteral feeding
E: non-specified
Mohan, 2006 [53] P Preterm infants (GA < 37 w) Bifidobacterium lactis BB12 FM Not stated
DB D: 1.6 × 109 CFU on day 1 to 3, and 4.8 × 109 CFU from
day 4 onwards
R S: first day of life
C Duration: 21 days
Oncel, 2013 [25] P Preterm infants with GA ≤ 32 w and BW≤ 1500 g, who
survived to feed enterally
Lactobacillus reuteri DSM 17938 HM, FM Oil base
DB D: 1 × 108 CFU OD
R S: first feed
C E: death or discharge
Patole, 2014 [45] P Preterm infants with GA < 33 w and BW < 1500 g Bifidobacterium breve M16-V HM, FM Dextrin
DB D: 3 × 109 CFU OD (1.5 × 109 CFU OD for newborns
≤ 27 w until they reached 50 ml/kg/day enteral feeds)
R S: start of enteral feed
C E: corrected age of 37 w
Rojas, 2012 [30] P Preterm infants with BW≤ 2000 g, hemodynamically
stable, ≤ 48 h of age (regardless start of enteral feeding)
Lactobacillus reuteri DSM 17938 HM, FM Oil base
DB D: 1 × 108 CFU OD
R S: age≤ 48 h
C E: death or discharge
Multic.
Rougé, 2009 [50] P Preterm infants with GA < 32 w and BW < 1500 g,
≤ 2 w of age, without any disease other than those
linked to prematurity, who started enteral feeding
before inclusion
Bifidobacterium longum BB536 OMM, DM or PFM MDX
DB Lactobacillus rhamnosus GG BB536-LGG
R Total D: 1 × 108 CFU/day
C S: start of enteral feeding
Bic. E: discharge
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Table 1 Studies included in the systematic review and meta-analysis (Continued)
Roy, 2014 [58] P Preterm infants (GA < 37w) and BW< 2500 g, with stable
enteral feeding within 72 h of birth
Lactobacillus acidophilus 1.25 × 109 CFU × 1 g HM Sterile water
DB B. longum 0.125 × 109 CFU × 1 g
R B. bifidum 0.125 × 109 CFU × 1 g
C B. lactis 1 × 109 CFU × 1 g
D: half a 1 g sachet
S: from 72 h of life
E: after 6 w or at discharge
Saengtawesin, 2014 [48] P Preterm infants with GA ≤ 34 w and BW≤ 1500 g Lactobacillus acidophilus 1 × 109 CFU HM, PFM None
R Bifidobacterium
C bifidum 1 × 109 CFU
D: 125 mg/kg BD
S: start of feeding
E: 6 w of age or discharge.
Samanta, 2009 P Preterm infants with GA < 32 w and BW < 1500 g, who
started enteral feeding and survived beyond 48 h of age
Bifidobacterium infantis HM None
DB Bifidobacterium bifidum
R Bifidobacterium longum
C Lactobacillus acidophilus
D: 2.5 × 109 CFU each probiotic, BD
S: start of enteral feeding
E: discharge
Sari, 2011 [34] P Preterm infants with GA < 32 w or BW < 1500 g, who
survived to feed enterally
Lactobacillus sporogenes HM, FM None
B D: 0.35 × 109 CFU OD
R S: first feed
C E: discharge
Serce, 2013 [27] P Preterm infants with GA ≤ 32 w and BW≤ 1500 g, who
survived to feed enterally
Saccharomyces boulardii HM, FM Distilled water
M D: 0.5 × 109 CFU/kg BD
R S: non-specified
C E: non-specified
Stratiki, 2007 [39] P Preterm infants with GA 27–32 w, formula-fed, without
major congenital anomalies
Bifidobacterium lactis FM None
B D: 2 × 107 CFU/g of milk powder
R S: start of enteral feeding
C E: non-specified
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Table 1 Studies included in the systematic review and meta-analysis (Continued)
Totsu, 2014 [46] P Infants with BW < 1500 g Bifidobacterium bifidum HM, FM Dextrin
DB D: 2.5 × 109 CFU, divided in two doses
CLR S: within 48 h after birth
C E: body weight 2000 g
Multic.
P prospective, DB double-blinded, R randomized, C controlled, Multic multicentric, B blinded, M masked, Bic bicentric, BW birth weight, GA gestational age, NEC necrotizing enterocolitis, HM human milk, CFU colony
forming unit, OD once daily, BD twice daily, OMM own mother’s milk, PFM preterm formula, DM donor milk, FM formula, MDX maltodextrin
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moderate, low and very low (as suggested by the GRADE
Working Group) [22].
The association between probiotic use and NEC was
evaluated by meta-analyses, conducted by AA and DG,
using the RevMan software (version 5.3.5; downloaded
from the Cochrane website: http://tech.cochrane.org/
revman/download). Risk ratio (RR) was calculated using
the Mantel-Haenszel method, and reported with 95 %
confidence interval (CI).
The following sub-meta-analyses were also performed,
in order to evaluate the effect of probiotics:
 in specific subgroups of patients (very-low-birth-weight
[VLBW] infants);
 in surgical NEC;
 according to NEC incidence in different populations:
the incidence of NEC stage ≥2 in the control
population was used as a reference, because only a
minority of studies reported NEC incidence in the
general population. Studies were arbitrarily divided
into three groups defined as “low-risk” (NEC
incidence <5 %), “medium-risk” (incidence 5–10 %),
and “high-risk” (incidence >10 %);
 according to probiotic strain: studies were divided
according to the specific probiotic strain used, and
were considered as suitable for inclusion in the
sub-meta-analyses when the same probiotic strain
was used in at least two studies. Studies which used
a probiotic mixture were considered together.
Microbiological quality of all the studies was evaluated
by MLC and LM. Studies were defined as having severe,
moderate or minor microbiological flaws according to
the evaluation of proper strain identification and micro-
biological assessment. Specifically, the lack of proper
strain identification was considered as a severe flaw; the
lack of microbiological assessment regarding the pro-
biotic persistence in stools was considered as a mod-
erate flaw, whereas a low flaw was defined when the
presence of the probiotic in stools was evaluated by
indirect approaches such as the quantification of its
species belonging.
A fixed-effect model was used for the analyses. Het-
erogeneity was measured using the I2 test. If significant
heterogeneity was present (p < 0.05 from the χ2 test), a
random-effects model was used [23]. The random-
effects model was also used when heterogeneity was not
significant but the number of studies was ≤ 5, because
the test for heterogeneity is known to have low power
when the number of studies is small [24].
Forest plots were used to illustrate results from meta-
analyses, and funnel plots to investigate bias.
The online version of GraphPad Quickcalcs software
was used to calculate number needed to treat (NNT).
Results
Literature search
Three-hundred-sixty-eight papers were identified through
the literature search (310 through PubMed and 58
through the Cochrane Library). Thirty-eight studies met
the inclusion criteria: 22 were identified through the
PubMed search [25–48] and 16 through the Cochrane Li-
brary search [25, 26, 28–32, 34–37, 40–43, 45]. Ten add-
itional papers were identified from the reference lists of
included studies [49–58]. Of these 47 studies, 16 were ex-
cluded, as they were duplicates retrieved both by PubMed
and Cochrane Library search. Six additional studies were
excluded after examining the full-texts: one study reported
maternal probiotic supplementation during pregnancy
[29], one cohort was reported twice [31], one study in-
cluded both term and preterm infants [36], two studies
did not report NEC data [55, 56], and in one study
randomization was not declared [54].
Twenty-six studies were suitable for inclusion in the
meta-analysis [10, 25–28, 30, 32–35, 37–42, 44, 46, 48–
53, 58]. A description of included studies is provided in
Table 1; excluded studies are described in Table 2.
All the studies reported NEC data in a form suitable
for meta-analysis, except one [53], for which data in-
cluded in a previous Cochrane review were used [59].
Table 2 Studies excluded from the systematic review and meta-analysis
Author, year Study summary Reason for exclusion
Awad, 2010 Living vs. killed Lactobacillus acidophilus vs. placebo given to neonates admitted
to the study NICU
Term and preterm infants included
Benor, 2014 Lactobacillus acidophilus and Bifidobacteria lactis vs. placebo given to mothers
of VLBW infants
Maternal probiotic supplementation
Li, 2004 Bifidobacterium breve given to LBW infants Randomization not declared
Millar, 1993 Lactobacillus GG given to preterm infants with GA < 33 w No NEC data
Reuman, 1986 Formula containing lactobacilli vs. placebo given to preterm infants No NEC data
Sari, 2012 Lactobacillus sporogenes given to preterm infants with GA< 32 w or BW< 1500 g,
who survived to feed enterally
Duplicate population (Sari, 2011 [34])
NICU neonatal intensive care unit, VLBW very low birth weight, LBW low birth weight, GA gestational age, NEC necrotizing enterocolitis, BW birth weight
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Table 3 Incidence of necrotizing enterocolitis in infants treated with probiotics and in controls
Author, year Previous NEC rate Number of subjects NEC in probiotic group NEC in control group
Al-Hosni, 2012 [33] Not stated 50 probiotic 3/50 any stage 4/51 any stage
51 control 1/50 stage 1 2/51 stage 1
0/50 stage 2 0/51 stage 2
2/50 stage 3 2/51 stage 3
Bin-Nun, 2005 [40] 15 % 72 probiotic 3/72 any stage 12/73 any stage
73 control 1/72 stage ≥2 10/73 stage ≥2
1/72 stage 2 7/73 stage 2
0/72 stage 3 3/73 stage 3
Braga, 2011 [35] 10 % 119 probiotic 0/119 stage ≥2 4/112 stage ≥2
112 placebo
Costalos, 2003 [49] Not stated 51 probiotic 5/51 any stage 6/36 any stage
36 placebo
Dani, 2002 [42] Not stated 295 probiotic 4/295 stage ≥2 8/290 stage ≥2
290 placebo
Demirel, 2013 [28] 32 % 135 probiotic 6/135 stage ≥2 7/136 stage ≥2
136 control
Dilli, 2015 [44] Not stated 100 probiotic 2/100 stage ≥2 18/100 stage ≥2
100 placebo
Fernández-Carrocera, 2013 [32] 20 % 75 probiotic 6/75 stage ≥2 12/75 stage ≥2
75 placebo
Jacobs, 2013 [26] Not stated 548 probiotic 11/548 stage ≥2 24/551 stage ≥2
551 placebo
Kitajima, 1997 [52] Not stated 45 probiotic 0/45 any stage 0/46 any stage
46 placebo
Lin, 2005 [41] Approx. 23 %
(NEC or death)
180 probiotic 2/180 stage ≥2 10/187 stage ≥2
187 control 2/180 stage 2 4/187 stage 2
0/180 stage 3 6/187 stage 3
Lin, 2008 [37] Approx. 217 placebo 4/217 any stage 14/217 any stage
217 control 2/217 stage 2 9/217 stage 2
2/217 stage 3 5/217 stage 3
Manzoni, 2006 [37] Not stated 39 probiotic 1/39 any stage 3/41 any stage
41 control 1/39 stage 2 2/41 stage 2
0/39 stage 3 1/41 stage 3
Mihatsch, 2010 [43] Not stated 84 probiotic 2/84 stage ≥2 4/82 stage ≥2
82 placebo
Mohan, 2006 [53] Not stated 21 probiotic 2/37 stage ≥2 1/32 stage ≥2
17 placebo Unpublished data, taken
from Alfaleh 2011 [58]
Unpublished data, taken
from Alfaleh 2011 [58]
Oncel, 2013 [25] 15 % 200 probiotic 8/200 stage ≥2 10/200 stage ≥2
200 placebo
Patole, 2014 [45] Not stated 74 probiotic 0/74 stage ≥2 1/66 stage ≥2
66 placebo
Rojas, 2012 [30] Not stated 372 probiotic NEC stage ≥2 NEC stage ≥2
378 placebo ≤1500 g ≤1500 g
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For each study, NEC rate in the probiotic and in the pla-
cebo/control group is reported in Table 3. For the purpose
of the meta-analysis, data on NEC stage ≥2 were used.
Probiotics and NEC stage ≥2
Data from 6605 infants (3324 in the probiotic group and
3281 in the control group) were analyzed. Fewer infants
in the probiotic group developed NEC stage ≥2 com-
pared to infants in the control group (88 [2.65 %] vs.
188 [5.73 %], respectively). The RR was significantly
lower in infants treated with probiotics (0.47 [95 % CI
0.36–0.60], p < 0.00001; fixed-effect analysis). NNT was
33 (95 % CI 24.7–47.2), which means that 33 infants
needed to be treated with probiotics in order to prevent
one more case of NEC stage ≥2. Heterogeneity among
trials was absent (I2 = 0 %, p = 0.63; Fig. 2a). The funnel
plot did not show any clear asymmetry (Fig. 2b).
VLBW infants
Twenty-two studies [25–28, 30, 32–35, 37, 38, 40–42,
44–46, 48, 50–52] reported data from 5912 VLBW in-
fants, 2959 in the probiotic and 2953 in the control
group. NEC stage ≥2 occurred less frequently in the pro-
biotic group than in controls (82 [2.77 %] infants vs. 174
[5.89 %], respectively), with a RR of 0.48 ([95 % CI 0.37–
0.62], p < 0.00001; fixed-effect analysis; I2 = 0 %, p =
0.56). NNT was 33 (95 % CI 24.1–47.9).
Surgical NEC
Only 6 studies [33, 34, 37, 40, 41, 51] reported separate
data for surgical NEC (NEC stage 3), which occurred in
6/668 (0.90 %) infants in the probiotic group and in 20/
680 (2.94 %) infants in the control group. The RR for NEC
stage 3 was significantly lower in the probiotic group (0.35
[95 % CI 0.16–0.81], p = 0.01; fixed-effect analysis; I2 =
0 %, p = 0.69). NNT was 49 (95 % CI 28.6–170.8).
NEC incidence
NEC incidence in controls was <5 % in 13 studies
(Fig. 3a) [26, 30, 33, 35, 42, 43, 45, 46, 48, 50, 52, 53, 58],
between 5 and 10 % in 8 studies (Fig. 3b) [25, 27, 28, 34,
37, 39, 41, 51], and >10 % in 5 studies (Fig. 3c) [32, 38,
40, 44, 49].
The RR for NEC stage ≥2 was significantly lower in
the probiotic group compared to the control group in all
the three populations (RR 0.52 [95 % CI 0.35–0.78], p =
0.001; RR 0.54 [95 % CI 0.36–0.80], p = 0.002; RR 0.33
[95 % CI 0.17–0.62], p = 0.0006, respectively). Hetero-
geneity was non-significant in all the three sub-analyses.
Probiotic strain
Lactobacillus GG was used in 2 studies [42, 51] and
Lactobacillus reuteri in 2 other studies [25, 30]: the ef-
fect of these probiotics in reducing NEC was not signifi-
cant, either for Lactobacillus GG and Lactobacillus
Table 3 Incidence of necrotizing enterocolitis in infants treated with probiotics and in controls (Continued)
6/176 probiotic 10/184 placebo
>1500 g >1500 g
3/196 probiotic 5/194 placebo
Rougé, 2009 [50] Not stated 45 probiotic 2/45 any stage 1/49 any stage
49 placebo
Roy, 2014 [58] Not stated 56 probiotic 2/56 any stage 2/56 any stage
56 placebo
Saengtawesin, 2014 [48] Not stated 31 probiotic 1/31 stage ≥2 1/29 stage ≥2
29 placebo
Samanta, 2009 Not stated 91 probiotic 5/91 stage ≥2 15/95 stage ≥2
95 control
Sari, 2011 [34] Approx. 32 %
(death or NEC)
110 probiotic 6/110 stage ≥2 10/111 stage ≥2
111 control 4/110 stage 2 7/111 stage 2
2/110 stage 3 3/111 stage 3
Serce, 2013 [27] 17 % 104 probiotic 7/104 stage ≥2 7/104 stage ≥2
104 placebo
Stratiki, 2007 [39] Not stated 41 probiotic 0/41 stage ≥2 3/34 stage ≥2
34 control
Totsu, 2014 [46] Not stated 153 probiotic 0/153 stage ≥1 0/130 stage ≥1
130 control
NEC necrotizing enterocolitis
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reuteri (RR 0.50 [95 % CI 0.17–1.44], p = 0.20 [Fig. 4a],
and RR 0.69 [95 % CI 0.38–1.26], p = 0.23 [Fig. 4b]). One
study used Lactobacillus sporogenes [34].
The results of all the studies including Lactobacilli
were pooled, except for the study by Sari et al. [34]:
Lactobacillus sporogenes is a species which has not an
international recognition, shows characteristics of both
genera Lactobacillus and Bacillus, and its strains should
be better classified as Bacillus coagulans [60]. Thus,
when the results of studies using Lactobacillus GG and
reuteri were pooled, no significant reduction in the RR
for NEC in the probiotic group was observed (0.62 [95
% CI 0.37–1.05], p = 0.07, Fig. 4c).
Four studies used Bifidobacterium lactis [39, 43,
44, 53], 2 studies Bifidobacterium breve [45, 52] and
1 study Bifidobacterium bifidum [46]. The use of
Fig. 2 Forest plot (2a) and funnel plot (2b) of the included studies. The forest plot shows the association between the use of probiotics and
necrotizing enterocolitis in the overall population of preterm infants. The funnel plot does not show any clear visual asymmetry. M-H:
Mantel-Haenszel method
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Bifidobacterium lactis resulted in a significant reduc-
tion in the RR for NEC (0.23 [95 % CI 0.10–0.55], p =
0.0008, Fig. 5a). No effect of Bifidobacterium breve in
reducing NEC was documented (RR 0.30 [95 % CI 0.01–
7.19], p = 0.46, Fig. 5b); the only study reporting the use of
Bifidobacterium bifidum did not report any case on NEC.
When the results of studies using Bifidobacteria were
pooled, a significant reduction in the RR for NEC in the
probiotic group was observed (0.24 [95 % CI 0.10–0.54],
p = 0.0006, Fig. 5c).
Saccharomyces boulardiiwas used in 3 studies [27, 28, 49]:
no significant effect of this probiotic was documented
(RR 0.81 [95 % CI 0.44–1.49], p = 0.50; random effects
analysis).
The pooled analysis of the 11 studies [26, 32, 33, 35,
37, 38, 40, 41, 48, 50, 58] in which a probiotic mixture
was used showed an overall and significant benefit of
these products in reducing NEC (RR 0.39 [95 % CI
0.27–0.56], p < 0.00001, Fig. 6).
Study quality
Evaluation of the quality of the studies included in the
meta-analysis according to the risk of bias tool as pro-
posed by the Cochrane Collaboration is showed in Table 4,
which also shows the level of evidence evaluated following
the recommendations of the GRADE Working Group.
Microbiological quality
Microbiological quality of included studies is described
in Table 5. Eight studies were evaluated as having severe
microbiological flaws [27, 32, 34, 35, 38, 40, 41, 49],
meaning that they did not report a proper probiotic
strain identification. Thirteen studies [25, 26, 28, 30, 33,
37, 42–44, 46, 48, 51, 58] were evaluated as having mod-
erate microbiological flaws, because none of them evalu-
ated the probiotic persistence in stools. There were only
five studies [39, 45, 50, 52, 53] with minor microbio-
logical flaws.
Fig. 3 Forest plot showing the association between the use of probiotics and necrotizing enterocolitis (NEC), according to NEC incidence:
(3a). NEC incidence < 5 %; (3b). NEC incidence 5–10 %; (3c). NEC incidence >10 %. M-H: Mantel-Haenszel method
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Discussion
The results of this systematic review and meta-analysis
show an overall benefit of probiotic supplementation for
the prevention of NEC in preterm infants. These results
are strengthened by the absence of significant statistical
heterogeneity among studies and by the low-risk of pub-
lication bias documented by the funnel plot.
However, despite the overall benefit, it is remarkable
that the 26 studies included in the meta-analysis were
extremely heterogeneous in terms of probiotic strain,
dosage, duration of intervention, and target population.
Furthermore, only few studies documented an effective
colonization of the infants’ gut with the probiotic strain.
Thus, the proposal made by the authors of the recent
Cochrane review of a “change in practice” in the use of
probiotics in preterm infants [11] might require further
investigation.
Currently available literature does not provide any def-
inite conclusion on which probiotic strain should be
used, and which group of preterm infants would benefit
most from a probiotic intervention. It is important to
note that the effect of a live-microorganism used as a
probiotic is strictly strain-specific [61]. In this paper we
aimed to perform strain-specific sub-meta-analyses but
our efforts were weakened by the fact that in very few
studies the same probiotic strain was used. For this rea-
son, we were unable to draw definite conclusions on
which single-strain of probiotics would be more effective
in reducing NEC. When studies using single strains were
pooled according to the probiotic genus, no significant
effect was documented for Lactobacilli and Saccharomy-
ces. This is partially in contrast with the recent Cochrane
review on probiotics and NEC [11], which showed a
beneficial effect of Lactobacilli: this discrepancy appears
to be due mainly to differences in the studies included
in the two sub-meta-analyses. Actually, the present
meta-analysis included the study by Oncel et al. [25],
which was on-going when the Cochrane review was
published, but excluded the study by Manzoni et al. [57],
where probiotics were used in addition to lactoferrin,
and the study by Sari et al. [34], which used a probiotic
product which is not properly a Lactobacillus [60].
The analysis of studies using Bifidobacteria showed a
significant effect of Bifidobacterium breve in reducing
NEC. This is also in contrast with the results of the
Cochrane review; however, the discrepancy is explained
by the inclusion in the present meta-analysis of the re-
cent study by Dilli et al. [44], which appears to drive the
beneficial effect documented for Bifidobacteria. Similarly
to the Cochrane review [11], the analysis of studies in
which more than one strain was used documented a
strong and significant effect of these products in the pre-
vention of NEC. No definite conclusion can be drawn
from these results, even if it could be suggested that fur-
ther research should be focused on mixed rather than
on single-strain products; a potential rationale for this
Fig. 4 Forest plot showing the association between probiotics and necrotizing enterocolitis in the studies which used a single-strain product
containing Lactobacilli ((4a). L. reuteri; (4b). L. GG; (4c). pooled analysis of all the studies using Lactobacilli). M-H: Mantel-Haenszel method
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approach could be that a mix of strains might be more
effective in providing an ecological barrier than a single
strain.
The evidence that probiotics are effective in reducing
NEC in VLBW infants does not necessarily apply also to
extremely LBW infants (ELBWs), who are the highest-
risk population. Only three studies [26, 33, 58] reported
the rate of NEC in ELBWs: in two of these studies
[33, 58], the same number of ELBWs in the probiotic
and control group developed NEC [33], while in the Pro-
Prems trial NEC incidence was slightly lower in the pro-
biotic group [26]. Given the relatively small number of
ELBWs and the inconclusive results, no specific recom-
mendation can be drawn from the analysis of these two
studies. Similarly, no study reported separate data for
intrauterine-growth-restricted (IUGR) infants, and thus
Fig. 5 Forest plot showing the association between probiotics and necrotizing enterocolitis in the studies which used a single-strain product
containing Bifidobacteria ((5a). B. lactis; (4b). B. breve; (4c). pooled analysis of all the studies using Bifidobacteria). M-H: Mantel-Haenszel method
Fig. 6 Forest plot showing the association between probiotics and necrotizing enterocolitis in the studies which used a probiotic mix. M-H:
Mantel-Haenszel method
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no recommendation can be made either for this high-
risk population.
In the analysis of trials evaluating a specific interven-
tion, it is pivotal to understand whether the results of
these trials are generalizable or applicable only in spe-
cific clinical settings. According to our data, the com-
mon belief that probiotics are more effective in
populations with a high rate of NEC [62] can be called
into question: actually, when studies were divided ac-
cording to NEC incidence in the control population,
NEC reduction was striking and significant also when
NEC rate in controls was extremely low. NEC rate in
controls can be considered as a proxy for the quality of
neonatal care: in this perspective, it is interesting to note
that, in contrast with previous data, probiotics appear to
confer a preventive benefit also in high quality-of-care
settings. NEC rate in control populations was used for
the analysis, rather than the baseline NEC rate stated by
the authors and used in several studies for sample size
calculation: this approach was considered more appro-
priate, because baseline NEC rate was not provided in
many studies and, when provided, there was often a dis-
crepancy with NEC rate detected in controls.
The analysis of included studies according to their
microbiological quality points out that clinical studies
aiming at evaluate the preventive effect of probiotics
on NEC often lack an adequate microbiological assess-
ment and this represents a major limitation of these
studies. Actually, it is well known that the correct
identification of a probiotic at species level corre-
sponds to evaluate its safety, whereas the identification
at strain level is extremely relevant as probiotic benefi-
cial properties are strain-specific. Furthermore, the
evaluation of probiotic colonisation, even if temporary,
Table 4 Evaluation of the quality of the studies included in the meta-analysis according to the risk of bias tool as proposed by the
Cochrane collaboration and evaluation of the level of evidence according to the GRADE approach
Study Random sequence
generation
Allocation
concealment
Blinding Incomplete
outcome data
Selective outome
reporting
Other sources
of bias
Levels of quality of evidence
in the grade approach
Al-Hosni, 2012 [33] UNCLEAR UNCLEAR LOW UNCLEAR UNCLEAR UNCLEAR LOW
Bin-Nun, 2005 [40] UNCLEAR UNCLEAR HIGH UNCLEAR UNCLEAR UNCLEAR VERYLOW
Braga, 2011 [35] LOW LOW LOW LOW UNCLEAR LOW HIGH
Costalos, 2003 [49] LOW LOW LOW LOW UNCLEAR LOW HIGH
Dani, 2002 [42] UNCLEAR LOW LOW LOW UNCLEAR UNCLEAR MODERATE
Demirel, 2013 [28] LOW LOW LOW UNCLEAR UNCLEAR UNCLEAR MODERATE
Dilli, 2015 [44] LOW LOW LOW UNCLEAR UNCLEAR UNCLEAR MODERATE
Fernández-Carrocera,
2013 [32]
LOW LOW LOW LOW UNCLEAR LOW HIGH
Jacobs, 2013 [26] LOW UNCLEAR LOW UNCLEAR UNCLEAR UNCLEAR LOW
Kitajima, 1997 [52] LOW UNCLEAR LOW UNCLEAR UNCLEAR LOW MODERATE
Lin, 2005 [41] LOW LOW LOW LOW UNCLEAR LOW HIGH
Lin, 2008 [37] LOW LOW LOW LOW UNCLEAR LOW HIGH
Manzoni, 2006 [37] LOW LOW LOW UNCLEAR UNCLEAR LOW MODERATE
Mihatsch, 2010 [43] LOW UNCLEAR LOW LOW UNCLEAR LOW MODERATE
Mohan, 2006 [53] UNCLEAR LOW LOW UNCLEAR UNCLEAR UNCLEAR LOW
Oncel, 2013 [25] LOW UNCLEAR LOW LOW UNCLEAR UNCLEAR MODERATE
Patole, 2014 [45] LOW LOW LOW LOW UNCLEAR LOW HIGH
Rojas, 2012 [30] LOW LOW LOW LOW UNCLEAR LOW HIGH
Rougé, 2009 [50] LOW UNCLEAR UNCLEAR UNCLEAR UNCLEAR HIGH LOW
Roy, 2014 [58] LOW UNCLEAR LOW LOW UNCLEAR UNCLEAR MODERATE
Saengtawesin, 2014
[48]
HIGH HIGH HIGH UNCLEAR UNCLEAR UNCLEAR LOW
Samanta, 2009 LOW LOW LOW UNCLEAR UNCLEAR UNCLEAR MODERATE
Sari, 2011 [34] LOW LOW LOW UNCLEAR UNCLEAR UNCLEAR MODERATE
Serce, 2013 [27] LOW LOW LOW UNCLEAR UNCLEAR LOW MODERATE
Stratiki, 2007 [39] UNCLEAR UNCLEAR LOW UNCLEAR UNCLEAR LOW LOW
Totsu, 2014 [46] LOW LOW LOW LOW UNCLEAR UNCLEAR MODERATE
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Table 5 Evaluation of the included studies according to their microbiological quality
Author, year Probiotic strain Strain identification Microbiological assessment Microbiological flaw
Al-Hosni, 2012 [33] Lactobacillus rhamnosus LGG LGG identified at the strain level No assessment Moderate
Bifidobacterium infantis B. infantis identified via the web site of
the producer: Bifantis (Bifidobacterium
infantis 35624)
Bin-Nun, 2005 [40] Bifidobacterium infantis Strains not identified at the strain level No assessment Severe
Streptococcus thermophilus
Bifidobacterium bifidus
Braga, 2011 [35] Lactobacillus casei Strains non identified clearly No assessment Severe
Bifidobacterium breve
Costalos, 2003 [49] Saccharomyces boulardii Strain not identified at the strain level S. boulardii not characterized
in stools.
Severe
Gut flora assessed by plate
count
Dani, 2002 [42] Lactobacillus rhamnosus GG Strain identified No assessment Moderate
Demirel, 2013 [28] Saccharomyces boulardii Strain identified No assessment Moderate
Dilli, 2015 [44] B. lactis Strain non identified at the strain level
but probably Bb12
No assessment Moderate
Fernández-Carrocera,
2013 [32]
Lactobacillus acidophilus Strains not identified at the strain level No assessment Severe
Lactobacillus rhamnosus
Lactobacillus casei
Lactobacillus plantarum
Bifidobacterium infantis
Streptococcus thermophilus
Jacobs, 2013 [26] Bifidobacterium infantis Strains identified at the strain level No assessment Moderate
Streptococcus thermophilus
Bifidobacterium lactis
Kitajima, 1997 [52] Bifidobacterium breve Strain identified Assessment by a strain-specific
monoclonal antibody
conjugated with colloidal
gold particle
Minor
Lin, 2005 [41] Lactobacillus acidophilus Strains not identified at the strain level No assessment Severe
Bifidobacterium infantis
Lin, 2008 [37] Lactobacillus acidophilus Strain identified No assessment Moderate
Bifidobacterium bifidum
Manzoni, 2006 [51] Lactobacillus rhamnosus LGG Strain identified No assessment Moderate
Mihatsch, 2010 [43] Bifidobacterium lactis Strain identified No assessment Moderate
Mohan, 2006 [53] Bifidobacterium lactis Strain identified Species-specific (not strain-
specific) assessment
Minor
Oncel, 2013 [25] Lactobacillus reuteri Strain identified No assessment Moderate
Patole, 2014 [45] Bifidobacterium breve Strain identified Microbiological assessment
by PCR
Minor
Rojas, 2012 [30] Lactobacillus reuteri Strain identified No assessment Moderate
Rougé, 2009 [50] Bifidobacterium longum Strain identified Microbiological assessment
by PCR
Minor
Lactobacillus rhamnosus GG
Roy, 2014 [58] Lactobacillus acidophilus,
B. longum, B. bifidum, and
B. lactis
Strains not identified at the strain
level/identification of the commercial
product
No assessment Moderate
Saengtawesin, 2014 [48] Lactobacillus acidophilus and
Bifidobacterium bifidum
No assessment Moderate
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is important to correlate the probiotic presence to the
beneficial effects.
The development of gut microbiota in preterm infants
is known to be influenced by several factors, including
gestational age, mode of delivery, diet, and antibiotic ex-
posure [63]. All these factors are likely to be significant
confounders in the relationship between probiotics and
NEC: actually, it is well documented that infants fed ma-
ternal or donor breast milk have a lower risk of NEC
compared to formula-fed infants [64], and that caesarean
delivery is associated with a disruption in gut microbiota
[65]. Quite surprisingly, however, in published studies
data are not analyzed taking these confounders into ac-
count [66]. Given the definite protective role of human
milk feeding and the symbiotic properties of human
milk, it would be fundamental to understand whether
the use of probiotics should be encouraged also in
human-milk fed infants, or if this intervention should be
directed towards exclusively formula-fed infants.
The studies included in the meta-analysis did not re-
port any short-term adverse effect of probiotic supple-
mentation (i.e., bloodstream infection with the probiotic
strain). Growing evidence suggests the influence of gut
microbiota on long-term health and disease, including
both type 1 and type 2 diabetes mellitus, atherosclerosis,
asthma, colon cancer, and inflammatory bowel disease
[67]. However, at present little is known on the long-
term outcome possibly related to the alteration of gut
flora in preterm infants, which is the result of the sup-
plementation with exogenous strains.
The choice to investigate a single outcome might be
viewed as a limitation of the study: however, this choice
was deliberate, as the literature search strategy was fo-
cused exclusively on NEC. Any speculation on different
outcomes such as sepsis or mortality would have been
inevitably misleading, because it would have been im-
possible to be sure to have identified all the studies
reporting on those outcomes.
Conclusions
Meta-analyses give a valuable contribution in guiding re-
searchers to focus future clinical studies on specific
unanswered questions. The results of the present meta-
analysis confirm that research on probiotics and NEC is
on the right track, but also suggest that there are several
unanswered questions which should be addressed before
radically changing clinical practice. Our data highlight
the need for further, well-designed studies aimed at
clarifying the specific effect of probiotics in high-risk
populations (i.e., ELBWs, IUGRs) and at addressing the
choice of the most effective probiotic product, at the
proper dose and duration of supplementation. For this
reason, we encourage, for future studies, the publication
of study protocols detailing study population and charac-
teristics of the intervention, in order to narrow probiotic
research to the most promising strains or combination of
strains and to the most vulnerable populations, thus
allowing a confirmative individual patient data analysis.
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